CA
CYTK icon

Cetera Advisors’s Cytokinetics CYTK Stock Holding History

Cetera Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$531K Buy
+7,579
New +$586K ﹤0.01% 1561

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Cetera Advisors's CYTK Position: Q1 2024 in Review

Cetera Advisors opened a new position in Cytokinetics (CYTK) in Q1 2024: 7,579 shares worth $531K. The stake represents ﹤0.01% of the portfolio and ranks #1561 among its holdings.

390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

  • Cetera Advisors held 7,579 shares of Cytokinetics worth $531K as of Q1 2024.
  • Cytokinetics was a new Cetera Advisors position in Q1 2024.
  • Cytokinetics made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1561 holding.
  • 390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.